Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2017-07-18 Earnings Release
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2017
Earnings Release Classification · 65% confidence The document is a company press release announcing second‐quarter 2017 net sales of DARZALEX and related royalty implications. It provides a single quarter highlight rather than full financial statements or presentation materials, matching the definition of an Earnings Release (initial announcement of quarterly/periodical financial results, key highlights only). Q2 2017
2017-07-18 English
Director's Dealing 2017
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details a transaction (Purchase of shares) by a 'Board member' (Rolf Hoffmann) involving the company's shares (Genmab A/S) on a specific date (2017-07-04). This structure perfectly matches the definition of a Director's Dealing report, which tracks personal share transactions by executives and directors.
2017-07-04 English
Director's Dealing 2017
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details transactions (specifically 'Sale of shares') conducted by senior management ('President & Chief Executive Officer', 'Executive Vice President & Chief Financial Officer') of the issuer (Genmab A/S). This type of mandatory filing, reporting insider trades by directors/executives, directly corresponds to the definition of Director's Dealing (DIRS).
2017-06-28 English
Director's Dealing 2017
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details specific transactions (subscription of shares, exercise of warrants) conducted by senior management (President & CEO, CFO) of the issuer (Genmab A/S) on specific dates. This perfectly matches the definition of Director's Dealing (insider trades by executives).
2017-06-27 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, the impact on total share capital, and the regulatory basis for the disclosure. This fits the definition of a 'Share Issue/Capital Change' (SHA) announcement, as it describes a specific change in the company's capital structure.
2017-06-27 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 95% confidence The document is a company announcement detailing an increase in share capital through the issuance of 163,164 new shares following the exercise of employee warrants. It provides subscription prices, share count details, and notes on listing and total nominal share capital post-increase—all hallmarks of a share issue or capital change announcement rather than a financial report or regulatory filing. Therefore, it fits the “Share Issue/Capital Change” category.
2017-06-27 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.